par D'Haene, Nicky 
;Maris, Calliope ;Rorive, Sandrine ;Decaestecker, Christine ;Le Mercier, Marie ;Salmon, Isabelle
Référence Glycobiology, 24, 10, page (892-898)
Publication Publié, 2014-10
;Maris, Calliope ;Rorive, Sandrine ;Decaestecker, Christine ;Le Mercier, Marie ;Salmon, Isabelle Référence Glycobiology, 24, 10, page (892-898)
Publication Publié, 2014-10
Article révisé par les pairs
| Résumé : | Despite advances in diagnosis and treatment, the overall outcomes for patients with brain tumors remain unpredictable. New prognostic markers are still needed to identify high-risk patients for whom the standard treatment has poor outcomes and would thus be well suited for more aggressive therapies. Neovascularization has long been implicated as a salient feature of glioma progression. In fact, high-grade gliomas are among the most vascular of all solid tumors, and vascular proliferation is a pathological hallmark of glioblastomas. Galectins are known to play important roles in cancer biology, including cancer cell migration, tumor immune escape or tumor angiogenesis. Moreover, galectins were reported to be involved in glioma progression. Given the key role of angiogenesis in brain tumors, the expression of galectins in tumor-associated endothelial cells (EC) and the implication of galectins in angiogenesis, the present review will focus on the expression of galectins in ECs of normal brain and brain tumors. |
